AOD9604

Name: AOD9604
Availability: InStock

2mg vial

AOD9604 is a modified fragment of the C-terminal region (amino acids 176–191) of human growth hormone (hGH), with an added disulphide bridge to enhance stability. Originally developed as an anti-obesity agent at Monash University, it isolates the fat-mobilising activity of hGH without the growth-promoting, insulin-resistance or IGF-1-elevating effects of the full hormone. It has progressed through Phase 2 clinical trials for obesity and is also studied for cartilage repair and metabolic applications.

Select size

Checking availability…

Researched for

Targeted lipolysis in adipose tissue without GH-receptor activation
No elevation of IGF-1, blood glucose or insulin resistance in trials
Phase 2 data showing favourable body-composition shifts
Investigational support for cartilage repair and osteoarthritis research
Favourable safety profile across human trials to date
Compatible with GLP-1 / metabolic peptide protocols in research stacks

Mechanism of action

Stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (formation of new adipose tissue) via mechanisms distinct from the GH receptor - believed to involve β3-adrenergic receptor pathways in adipose tissue. Does not bind the GH receptor, so it does not elevate IGF-1, impair glucose tolerance or stimulate skeletal growth.

Research protocol

Common research protocols use 250–500mcg subcutaneously once daily, typically administered in a fasted morning state to align with peak lipolytic activity. Cycles often run 8–12 weeks. Higher 500mcg–1mg daily doses are reported in obesity-focused research.

Half-life

Plasma half-life approx. 30 minutes; biological activity on adipocytes persists longer through downstream signalling.

Reconstitution

Reconstitute a 5mg vial with 1–2mL bacteriostatic water for a 2.5–5mg/mL working concentration. Swirl gently down the side of the vial - do not shake.

Storage

Lyophilised: 2–8°C, stable approx. 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations

• Magnitude of weight loss in human trials has been modest compared with GLP-1-class agents.
• Most efficacy data sits at Phase 2; no Phase 3 obesity approval has been completed.
• Mild injection-site reactions reported; long-term safety data beyond trial durations remains limited.